Asco Plc.

News & Analysis

asco plc. and company - All News and Analysis

• ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Findings with Trastuzumab-DM1 at ASCO

  - 2008-06-03

  WALTHAM, Mass. -- ImmunoGen, Inc. (Nasdaq: IMGN) announced today the presentation of encouraging clinical findings with trastuzumab-DM1 (T-DM1) at the 2008 American Society of Clinical Oncology ASCO Annual Meeting taking place in Chicago, IL. T-DM1 comprises ImmunoGen's DM1 cell-killing agent linked to Genentech's HER2-targeting antibody, trastuzumab. Genentech is developing T-DM1...

  Tags: Asco Plc., Genentech Inc., Company, ImmunoGen Inc.

• New Data from Several Satraplatin Clinical Trials in Solid Tumors Presented at 44th ASCO Annual Meeting

  - 2008-06-02

  MARTINSRIED/MUNICH, Germany & PRINCETON, N.J. -- GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced the presentation of data from several satraplatin clinical trials at the 44th Annual Meeting of the American Society for Clinical Oncology ASCO in Chicago. "We are pleased that data from several satraplatin...

  Tags: Asco Plc., Company, GPC Biotech AG

• Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting

  - 2008-06-02

  MARTINSRIED/MUNICH, Germany & PRINCETON, N.J. -- GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced the presentation of the overall survival results from the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial Satraplatin and Prednisone Against Refractory Cancer. The data were presented at the 44th Annual...

  Tags: Asco Plc., Company, GPC Biotech AG

• TransMolecular Reports Positive Results from Phase 1 Trial of Iodine-TM601 in Metastatic Melanoma

  - 2008-06-02

  - ASCO abstract re-confirms that intravenous radiolabeled TM601 can cross the blood-brain barrier and bind to tumor tissue- CAMBRIDGE, Mass. -- TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, today announced positive interim Phase 1 data for its intravenous formulation of 131I-TM601 in metastatic melanoma in...

  Tags: Asco Plc., Company, TransMolecular Inc.

• Gloucester Pharmaceuticals Announces Presentation of Romidepsin Phase 1 Data in Multiple Solid Tumors at ASCO

  - 2008-06-02

  Romidepsin/Gemcitabine Combination Warrants Further Exploration CAMBRIDGE, Mass. -- Gloucester Pharmaceuticals today announced results from a Phase 1 study of romidepsin in combination with gemcitabine in patients with solid tumors. The results from the Phase 1 study showed that the combination was generally well tolerated and indicated that further investigation...

  Tags: Asco Plc., Company

• Research Update

  - 2008-06-02

  Protherics PLC ProlarixTM phase 1 data to be presented at the American Society of Clinical Oncology ASCO Annual Meeting London, UK; Brentwood, TN, US; 2 June 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today...

  Tags: Asco Plc., Company, Protherics Plc.

• MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting

  - 2008-06-02

  MethylGene Inc. (TSX: MYG) today announced preliminary data from two ongoing clinical studies with MGCD0103, a novel, isoform-selective histone deacetylase HDAC inhibitor, conducted in collaboration with Celgene Corporation and Taiho Pharmaceutical. Results from a Phase II study evaluating MGCD0103 as a single-agent in Hodgkin lymphoma HL (Trial 010) were reported...

  Tags: Asco Plc., Company, MethylGene Inc.

• Data Presented at ASCO Identify Maximum Tolerated Dose and Confirm c-Met Inhibition in Tumors with ARQ 197, Under Development by ArQule

  - 2008-06-01

  CHICAGO -- Investigators today presented data from a Phase 1, dose-escalation trial with ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase under development by ArQule, Inc. (NASDAQ: ARQL). These data demonstrate that the compound is safe and well tolerated at oral doses up to 300 milligrams mg...

  Tags: ArQule Inc., Asco Plc., Company

• ImmunoGen, Inc. Announces Clinical Findings Reported at ASCO with Targeted Anticancer Compounds IMGN242 and AVE1642

  - 2008-06-01

  WALTHAM, Mass. -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that encouraging clinical findings with the targeted anticancer compounds IMGN242 and AVE1642 were reported at the 2008 American Society of Clinical Oncology ASCO Annual Meeting taking place in Chicago, IL.

  Tags: Asco Plc., Company, ImmunoGen Inc.

• GPC Biotech Announces Data from Several Satraplatin Clinical Trials to be Presented at ASCO Annual Meeting

  - 2008-05-28

  MARTINSRIED/MUNICH, Germany & PRINCETON, N.J. -- GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced that data from several satraplatin clinical trials will be presented at the 44th American Society of Clinical Oncology ASCO Annual Meeting taking place in Chicago, Ill., May 30-June 3, 2008. Details are...

  Tags: Asco Plc., Company, GPC Biotech AG